BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 31751333)

  • 1. Insufficiency of annual praziquantel treatment to control Schistosoma mansoni infections in adult women: A longitudinal cohort study in rural Tanzania.
    Mishra P; Colombe S; Paul N; Mlingi J; Tosiri I; Aristide C; Gao J; Kashangaki P; Nagai H; Kalluvya SE; de Dood CJ; Corstjens PL; Mngara J; van Dam GJ; Downs JA
    PLoS Negl Trop Dis; 2019 Nov; 13(11):e0007844. PubMed ID: 31751333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of two closely spaced doses of praziquantel against Schistosoma haematobium and S. mansoni and re-infection patterns in school-aged children in Niger.
    Garba A; Lamine MS; Barkiré N; Djibo A; Sofo B; Gouvras AN; Labbo R; Sebangou H; Webster JP; Fenwick A; Utzinger J
    Acta Trop; 2013 Nov; 128(2):334-44. PubMed ID: 22940014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of praziquantel in preschool-aged children in an area co-endemic for Schistosoma mansoni and S. haematobium.
    Coulibaly JT; N'gbesso YK; Knopp S; Keiser J; N'Goran EK; Utzinger J
    PLoS Negl Trop Dis; 2012; 6(12):e1917. PubMed ID: 23236526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of serum-based real-time PCR to detect Schistosoma mansoni infection before and after treatment.
    Fuss A; Mazigo HD; Mueller A
    Infect Dis Poverty; 2020 Jun; 9(1):74. PubMed ID: 32571433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of praziquantel treatment of Schistosoma mansoni during pregnancy on intensity of infection and antibody responses to schistosome antigens: results of a randomised, placebo-controlled trial.
    Tweyongyere R; Mawa PA; Emojong NO; Mpairwe H; Jones FM; Duong T; Dunne DW; Vennervald BJ; Katunguka-Rwakishaya E; Elliott AM
    BMC Infect Dis; 2009 Mar; 9():32. PubMed ID: 19296834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intestinal schistosomiasis of Ijinga Island, north-western Tanzania: prevalence, intensity of infection, hepatosplenic morbidities and their associated factors.
    Mueller A; Fuss A; Ziegler U; Kaatano GM; Mazigo HD
    BMC Infect Dis; 2019 Oct; 19(1):832. PubMed ID: 31590657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Praziquantel treatment of school children from single and mixed infection foci of intestinal and urogenital schistosomiasis along the Senegal River Basin: monitoring treatment success and re-infection patterns.
    Webster BL; Diaw OT; Seye MM; Faye DS; Stothard JR; Sousa-Figueiredo JC; Rollinson D
    Acta Trop; 2013 Nov; 128(2):292-302. PubMed ID: 23022016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotypic and genotypic monitoring of Schistosoma mansoni in Tanzanian schoolchildren five years into a preventative chemotherapy national control programme.
    Gower CM; Gehre F; Marques SR; Lamberton PHL; Lwambo NJ; Webster JP
    Parasit Vectors; 2017 Dec; 10(1):593. PubMed ID: 29197426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy of one versus two doses of praziquantel on cure rate of Schistosoma mansoni infection and re-infection in Mayuge District, Uganda.
    Tukahebwa EM; Vennervald BJ; Nuwaha F; Kabatereine NB; Magnussen P
    Trans R Soc Trop Med Hyg; 2013 Jun; 107(6):397-404. PubMed ID: 23596262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology, immunology and chemotherapy of Schistosoma mansoni infections in a recently exposed community in Senegal.
    Gryseels B; Stelma FF; Talla I; van Dam GJ; Polman K; Sow S; Diaw M; Sturrock RF; Doehring-Schwerdtfeger E; Kardorff R
    Trop Geogr Med; 1994; 46(4 Spec No):209-19. PubMed ID: 7825223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and side effects of praziquantel against Schistosoma mansoni in a community of western Côte d'Ivoire.
    Raso G; N'Goran EK; Toty A; Luginbühl A; Adjoua CA; Tian-Bi NT; Bogoch II; Vounatsou P; Tanner M; Utzinger J
    Trans R Soc Trop Med Hyg; 2004 Jan; 98(1):18-27. PubMed ID: 14702835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five-Year Impact of Different Multi-Year Mass Drug Administration Strategies on Childhood
    Shen Y; Wiegand RE; Olsen A; King CH; Kittur N; Binder S; Zhang F; Whalen CC; Secor WE; Montgomery SP; Mwinzi PNM; Magnussen P; Kinung'hi S; Campbell CH; Colley DG
    Am J Trop Med Hyg; 2019 Dec; 101(6):1336-1344. PubMed ID: 31407653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-year longitudinal survey reveals high genetic diversity of Schistosoma mansoni with adult worms surviving praziquantel treatment at the start of mass drug administration in Uganda.
    Faust CL; Crotti M; Moses A; Oguttu D; Wamboko A; Adriko M; Adekanle EK; Kabatereine N; Tukahebwa EM; Norton AJ; Gower CM; Webster JP; Lamberton PHL
    Parasit Vectors; 2019 Dec; 12(1):607. PubMed ID: 31881923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetics and Pharmacodynamics of Praziquantel in Ugandan Children with Intestinal Schistosomiasis: Higher Dosages Are Required for Maximal Efficacy.
    Bustinduy AL; Waterhouse D; de Sousa-Figueiredo JC; Roberts SA; Atuhaire A; Van Dam GJ; Corstjens PL; Scott JT; Stanton MC; Kabatereine NB; Ward S; Hope WW; Stothard JR
    mBio; 2016 Aug; 7(4):. PubMed ID: 27507822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of praziquantel and reinfection patterns in single and mixed infection foci for intestinal and urogenital schistosomiasis in Cameroon.
    Tchuem Tchuenté LA; Momo SC; Stothard JR; Rollinson D
    Acta Trop; 2013 Nov; 128(2):275-83. PubMed ID: 23791803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the Impact of Different Mass Drug Administration Strategies on Infection with
    Olsen A; Kinung'hi S; Magnussen P
    Am J Trop Med Hyg; 2018 Dec; 99(6):1573-1579. PubMed ID: 30350779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitivity and specificity of multiple Kato-Katz thick smears and a circulating cathodic antigen test for Schistosoma mansoni diagnosis pre- and post-repeated-praziquantel treatment.
    Lamberton PH; Kabatereine NB; Oguttu DW; Fenwick A; Webster JP
    PLoS Negl Trop Dis; 2014 Sep; 8(9):e3139. PubMed ID: 25211217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of praziquantel syrup (Epiquantel®) against Schistosoma haematobium and Schistosoma mansoni in preschool-aged children in Niger.
    Garba A; Lamine MS; Djibo A; Tahirou A; Aouami MA; Alfari A; Phillips AE; Fenwick A; Utzinger J
    Acta Trop; 2013 Nov; 128(2):318-25. PubMed ID: 23237719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of single versus four repeated doses of praziquantel against Schistosoma mansoni infection in school-aged children from Côte d'Ivoire based on Kato-Katz and POC-CCA: An open-label, randomised controlled trial (RePST).
    Hoekstra PT; Casacuberta-Partal M; van Lieshout L; Corstjens PLAM; Tsonaka R; Assaré RK; Silué KD; Meité A; N'Goran EK; N'Gbesso YK; Amoah AS; Roestenberg M; Knopp S; Utzinger J; Coulibaly JT; van Dam GJ
    PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008189. PubMed ID: 32196506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increases in levels of schistosome-specific immunoglobulin E and CD23(+) B cells in a cohort of Kenyan children undergoing repeated treatment and reinfection with Schistosoma mansoni.
    Black CL; Muok EM; Mwinzi PN; Carter JM; Karanja DM; Secor WE; Colley DG
    J Infect Dis; 2010 Aug; 202(3):399-405. PubMed ID: 20560767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.